86 related articles for article (PubMed ID: 15243630)
1. Use of the EGP-2/Ep-CAM promoter for targeted expression of heterologous genes in carcinoma derived cell lines.
McLaughlin PM; Trzpis M; Kroesen BJ; Helfrich W; Terpstra P; Dokter WH; Ruiters MH; de Leij LF; Harmsen MC
Cancer Gene Ther; 2004 Sep; 11(9):603-12. PubMed ID: 15243630
[TBL] [Abstract][Full Text] [Related]
2. The carcinoma-specific epithelial glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context.
Gommans WM; van Eert SJ; McLaughlin PM; Harmsen MC; Yamamoto M; Curiel DT; Haisma HJ; Rots MG
Cancer Gene Ther; 2006 Feb; 13(2):150-8. PubMed ID: 16096650
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression.
Tai KY; Shiah SG; Shieh YS; Kao YR; Chi CY; Huang E; Lee HS; Chang LC; Yang PC; Wu CW
Oncogene; 2007 Jun; 26(27):3989-97. PubMed ID: 17213811
[TBL] [Abstract][Full Text] [Related]
4. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy.
McLaughlin PM; Harmsen MC; Dokter WH; Kroesen BJ; van der Molen H; Brinker MG; Hollema H; Ruiters MH; Buys CH; de Leij LF
Cancer Res; 2001 May; 61(10):4105-11. PubMed ID: 11358833
[TBL] [Abstract][Full Text] [Related]
5. An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy.
McLaughlin PM; Kroesen BJ; Dokter WH; van der Molen H; de Groot M; Brinker MG; Kok K; Ruiters MH; Buys CH; de Leij LF
Cancer Immunol Immunother; 1999 Sep; 48(6):303-11. PubMed ID: 10473805
[TBL] [Abstract][Full Text] [Related]
6. Targeted gene expression using a 1.1 kilobase promoter fragment of the tumour-associated antigen EpCAM.
Gires O; Pöckl S; Chapman RD; Münz M
Anticancer Res; 2004; 24(6):3715-21. PubMed ID: 15736402
[TBL] [Abstract][Full Text] [Related]
7. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.
Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL
Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703
[TBL] [Abstract][Full Text] [Related]
8. Engineering zinc finger protein transcription factors to downregulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment.
Gommans WM; McLaughlin PM; Lindhout BI; Segal DJ; Wiegman DJ; Haisma HJ; van der Zaal BJ; Rots MG
Mol Carcinog; 2007 May; 46(5):391-401. PubMed ID: 17186549
[TBL] [Abstract][Full Text] [Related]
9. [Targeted killing of colorectal tumor cells by lentiviral constructs containing CD/TK suicide genes and KDR promoter].
Chen HJ; Huang ZH; Wu AG; Yu JL; Su GQ
Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):624-7. PubMed ID: 17545072
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells.
Koshikawa N; Takenaga K; Tagawa M; Sakiyama S
Cancer Res; 2000 Jun; 60(11):2936-41. PubMed ID: 10850440
[TBL] [Abstract][Full Text] [Related]
11. [In vitro treatment of ovarian cancer cells with cytosine deaminase-thymidine kinase fusion disuicide gene therapy system under the control of human telomerase reverse transcriptase gene promoter].
Kong BH; Song Y; Ma DX; Qu X; Jiang S
Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):390-5. PubMed ID: 15312323
[TBL] [Abstract][Full Text] [Related]
12. Suicide gene therapy using keratin 19 enhancer and promoter in malignant mesothelioma cells.
Ishiwata N; Inase N; Fujie T; Tamaoka M; Yoshizawa Y
Anticancer Res; 2003; 23(2B):1405-9. PubMed ID: 12820402
[TBL] [Abstract][Full Text] [Related]
13. Growth-responsive expression from the murine thymidine kinase promoter: genetic analysis of DNA sequences.
Fridovich-Keil JL; Gudas JM; Dou QP; Bouvard I; Pardee AB
Cell Growth Differ; 1991 Feb; 2(2):67-76. PubMed ID: 2069870
[TBL] [Abstract][Full Text] [Related]
14. Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue.
Spizzo G; Gastl G; Obrist P; Fong D; Haun M; Grünewald K; Parson W; Eichmann C; Millinger S; Fiegl H; Margreiter R; Amberger A
Cancer Lett; 2007 Feb; 246(1-2):253-61. PubMed ID: 16624485
[TBL] [Abstract][Full Text] [Related]
15. [Adenovirus-mediated double suicide gene selectively kills breast cancer MCF-7 cells in vitro].
Kong H; Huang ZH; Li Q; Yang LC; Yu JL; Li Z
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):907-10. PubMed ID: 18583225
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modifications affect Dnmt3L expression.
Aapola U; Mäenpää K; Kaipia A; Peterson P
Biochem J; 2004 Jun; 380(Pt 3):705-13. PubMed ID: 15015937
[TBL] [Abstract][Full Text] [Related]
17. The proximal promoter of the human cathepsin G gene conferring myeloid-specific expression includes C/EBP, c-myb and PU.1 binding sites.
Lennartsson A; Garwicz D; Lindmark A; Gullberg U
Gene; 2005 Aug; 356():193-202. PubMed ID: 16019164
[TBL] [Abstract][Full Text] [Related]
18. [Construction of a plasmid vector of fused protein genes driven by human insulin-like growth factor II P3 promoter].
Zhou HK; Yang DH; Tang SH; Huang W; Lu XH
Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(2):106-10. PubMed ID: 16620715
[TBL] [Abstract][Full Text] [Related]
19. The mouse chemerin receptor gene, mcmklr1, utilizes alternative promoters for transcription and is regulated by all-trans retinoic acid.
Mårtensson UE; Bristulf J; Owman C; Olde B
Gene; 2005 Apr; 350(1):65-77. PubMed ID: 15792532
[TBL] [Abstract][Full Text] [Related]
20. Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors.
Ren-Heidenreich L; Hayman GT; Trevor KT
Hum Gene Ther; 2000 Jan; 11(1):9-19. PubMed ID: 10646635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
